

Davide Franceschini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7727766/publications.pdf>

Version: 2024-02-01

119
papers

2,091
citations

201385

27
h-index

329751

37
g-index

121
all docs

121
docs citations

121
times ranked

3206
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 710-718.	1.0	5
2	Oligoscore: a clinical score to predict overall survival in patients with oligometastatic disease treated with stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2022, 61, 553-559.	0.8	2
3	Unmet needs in the management of unresectable stage III non-small cell lung cancer: a review after the "radio talk"™ webinars. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 549-559.	1.1	1
4	Locally Advanced Non-Small Cell Lung Cancer: Clinical Outcome, Toxicity and Predictive Factors in Patients Treated with Hypofractionated Sequential or Exclusive Radiotherapy. <i>Current Oncology</i> , 2022, 29, 4893-4901.	0.9	0
5	Preliminary Results of a Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation Versus Accelerated Partial Breast Irradiation (HYPAB Trial). <i>Clinical Breast Cancer</i> , 2021, 21, 231-238.	1.1	15
6	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 133-140.	1.0	6
7	Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 396-404.	1.0	8
8	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. <i>European Journal of Cancer</i> , 2021, 143, 75-77.	1.3	7
9	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 927-936.	1.2	9
10	Comparing hypofractionated and conventionally fractionated whole breast irradiation for patients with ductal carcinoma in situ after breast conservation: a propensity score-matched analysis from a national multicenter cohort (COBCG-02 study). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2069-2077.	1.2	3
11	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 101-110.	0.3	3
12	Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma. <i>Lung Cancer</i> , 2021, 152, 1-6.	0.9	7
13	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. <i>Medical Oncology</i> , 2021, 38, 48.	1.2	4
14	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. <i>Practical Radiation Oncology</i> , 2021, 11, e329-e338.	1.1	4
15	A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy". <i>Lung Cancer</i> , 2021, 157, 165-166.	0.9	2
16	Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment. <i>Cancers</i> , 2021, 13, 3590.	1.7	21
17	Ipsilateral Breast Cancer Recurrence: Characteristics, Treatment, and Long-Term Oncologic Results at a High-Volume Center. <i>Clinical Breast Cancer</i> , 2021, 21, 329-336.	1.1	7
18	Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 7009-7031.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3619-3625.	1.2	5
20	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, e767-e773.	1.1	8
21	Impact of hypofractionated schemes in radiotherapy for locally advanced head and neck cancer patients. <i>Laryngoscope</i> , 2020, 130, E163-E170.	1.1	11
22	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 213-221.	1.0	29
23	Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience. <i>Clinical Lung Cancer</i> , 2020, 21, 86-93.	1.1	4
24	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. <i>Radiologia Medica</i> , 2020, 125, 214-219.	4.7	10
25	The Potential Role of Intensity-modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A Treatment Planning Study. <i>Clinical Oncology</i> , 2020, 32, 26-34.	0.6	22
26	A radiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 922-931.	1.0	12
27	Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. <i>British Journal of Radiology</i> , 2020, 93, 20190627.	1.0	11
28	Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with a curative intent. <i>Lung Cancer</i> , 2020, 141, 1-8.	0.9	17
29	Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 743-753.	1.1	1
30	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. <i>Radiation Oncology</i> , 2020, 15, 92.	1.2	31
31	Liver Metastases-directed Therapy in the Management of Oligometastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 480-486.	1.1	10
32	Hypofractionated Whole Breast Irradiation and Simultaneous Integrated Boost in Large-breasted Patients: Long-term Toxicity and Cosmesis. <i>Clinical Breast Cancer</i> , 2020, 20, 527-533.	1.1	11
33	Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2289-2297.	1.2	12
34	Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2267-2276.	1.2	7
35	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 565-573.	1.7	9
36	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. <i>Radiotherapy and Oncology</i> , 2020, 150, 184-190.	0.3	12

#	ARTICLE	IF	CITATIONS
37	The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102894.	2.0	27
38	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1227-1234.	1.2	5
39	Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkinâ€™s lymphoma. Assessment of risk of toxicity and secondary cancer induction. <i>Radiation Oncology</i> , 2020, 15, 12.	1.2	14
40	Current radiotherapy techniques in NSCLC: challenges and potential solutions. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 387-402.	1.1	24
41	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 608-616.	1.0	8
42	Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 885.	1.7	10
43	Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation. <i>British Journal of Radiology</i> , 2019, 92, 20190252.	1.0	8
44	RapidPlan knowledge based planning: iterative learning process and model ability to steer planning strategies. <i>Radiation Oncology</i> , 2019, 14, 187.	1.2	39
45	Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach. <i>PLoS ONE</i> , 2019, 14, e0224027.	1.1	5
46	Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2469-2479.	1.2	14
47	Surgery Followed by Hypofractionated Radiosurgery on the Tumor Bed in Oligometastatic Patients With Large Brain Metastases. Results of a Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1095-1105.	0.4	15
48	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. <i>British Journal of Radiology</i> , 2019, 92, 20181026.	1.0	4
49	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210758.	1.1	58
50	Predicting survival and local control after radiochemotherapy in locally advanced head and neck cancer by means of computed tomography based radiomics. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 805-818.	1.0	36
51	Postmastectomy radiation therapy using VMAT technique for breast cancer patients with expander reconstruction. <i>Medical Oncology</i> , 2019, 36, 48.	1.2	25
52	Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity. <i>British Journal of Radiology</i> , 2019, 92, 20190021.	1.0	6
53	Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 614-621.	0.4	22
54	Extra-pleural pneumonectomy in the era of image-guided intensity-modulated radiotherapy. <i>Radiologia Medica</i> , 2019, 124, 854-859.	4.7	9

#	ARTICLE	IF	CITATIONS
55	Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 111-121.	0.4	30
56	Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group. <i>Radiologia Medica</i> , 2019, 124, 662-670.	4.7	33
57	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 3775-3782.	1.1	10
58	Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. <i>Radiologia Medica</i> , 2019, 124, 315-322.	4.7	11
59	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 220-226.	0.3	49
60	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO)â€™Lung Working Group. <i>Radiologia Medica</i> , 2019, 124, 136-144.	4.7	8
61	Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2019, 201, 70-76.	0.2	44
62	Title is missing!. , 2019, 14, e0224027.		0
63	Title is missing!. , 2019, 14, e0224027.		0
64	Title is missing!. , 2019, 14, e0224027.		0
65	Title is missing!. , 2019, 14, e0224027.		0
66	Title is missing!. , 2019, 14, e0224027.		0
67	Title is missing!. , 2019, 14, e0224027.		0
68	Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. <i>Radiotherapy and Oncology</i> , 2018, 127, 326-331.	0.3	17
69	Hypofractionated volumetric modulated arc therapy in ductal carcinoma <i>in situ</i> : toxicity and cosmetic outcome from a prospective series. <i>British Journal of Radiology</i> , 2018, 91, 20170634.	1.0	4
70	Critical Appraisal of the Risk of Secondary Cancer Induction From Breast Radiation Therapy With Volumetric Modulated Arc Therapy Relative to 3D Conformal Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 785-793.	0.4	29
71	Radiation therapy in small cell lung cancer: a national Italian survey. <i>Radiologia Medica</i> , 2018, 123, 554-560.	4.7	3
72	Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Breast Cancer Treated with Surgery Followed by Radiotherapy. <i>World Neurosurgery</i> , 2018, 110, e281-e286.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Stereotactic Body Radiation Therapy in Oligometastatic Ovarian Cancer: A Promising Therapeutic Approach. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1507-1513.	1.2	35
74	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	3.4	38
75	Critical Appraisal of the Treatment Planning Performance of Volumetric Modulated Arc Therapy by Means of a Dual Layer Stacked Multileaf Collimator for Head and Neck, Breast, and Prostate. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880388.	0.8	26
76	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 951-956.	0.5	8
77	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. <i>Cancer Medicine</i> , 2018, 7, 4379-4386.	1.3	29
78	Hypofractionation with simultaneous boost in breast cancer patients receiving adjuvant chemotherapy: A prospective evaluation of a case series and review of the literature. <i>Breast</i> , 2018, 42, 31-37.	0.9	14
79	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	0.8	80
80	The role of SBRT in oligometastatic patients with liver metastases from breast cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 163-169.	0.3	14
81	Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 385-391.	1.0	7
82	Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. <i>British Journal of Radiology</i> , 2017, 90, 20170022.	1.0	5
83	Organs at risk in lung SBRT. <i>Physica Medica</i> , 2017, 44, 131-138.	0.4	24
84	RapidPlan head and neck model: the objectives and possible clinical benefit. <i>Radiation Oncology</i> , 2017, 12, 73.	1.2	66
85	Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1293-1299.	1.2	26
86	Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. <i>British Journal of Radiology</i> , 2017, 90, 20170422.	1.0	13
87	Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. <i>British Journal of Radiology</i> , 2017, 90, 20170257.	1.0	14
88	Dosimetric trade-offs in breast treatment with VMAT technique. <i>British Journal of Radiology</i> , 2017, 90, 20160701.	1.0	51
89	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. <i>World Neurosurgery</i> , 2017, 105, 184-190.	0.7	13
90	Minimally Invasive Stereotactical Radio-ablation of Adrenal Metastases as an Alternative to Surgery. <i>Cancer Research and Treatment</i> , 2017, 49, 20-28.	1.3	34

#	ARTICLE	IF	CITATIONS
91	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. <i>BMC Cancer</i> , 2017, 17, 829.	1.1	77
92	Critical appraisal of the role of volumetric modulated arc therapy in the radiation therapy management of breast cancer. <i>Radiation Oncology</i> , 2017, 12, 200.	1.2	26
93	Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis. <i>Anticancer Research</i> , 2017, 37, 7057-7062.	0.5	6
94	High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients. <i>Clinical Oncology</i> , 2016, 28, e173-e178.	0.6	33
95	Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical resection. <i>Radiation Oncology</i> , 2016, 11, 76.	1.2	59
96	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. <i>Cancer Treatment Reviews</i> , 2016, 50, 1-8.	3.4	30
97	Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results. <i>Radiation Oncology</i> , 2016, 11, 120.	1.2	38
98	Role of Stereotactic Body Radiation Therapy with Volumetric-Modulated Arcs and High-Intensity Photon Beams for the Treatment of Abdomino-Pelvic Lymph-Node Metastases. <i>Cancer Investigation</i> , 2016, 34, 348-354.	0.6	16
99	Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. <i>Breast</i> , 2016, 26, 11-17.	0.9	51
100	Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy. <i>Radiologia Medica</i> , 2016, 121, 229-237.	4.7	7
101	CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. <i>World Journal of Urology</i> , 2016, 34, 311-317.	1.2	28
102	Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. <i>Oncotarget</i> , 2016, 7, 53321-53329.	0.8	13
103	Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy. <i>Radiation Oncology</i> , 2015, 10, 224.	1.2	22
104	Cyberknife Treatment for Low and Intermediate Risk Prostate Cancer. <i>Cancer Investigation</i> , 2015, 33, 188-192.	0.6	7
105	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 507-515.	0.4	36
106	Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. <i>World Journal of Urology</i> , 2015, 33, 1197-1203.	1.2	35
107	Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. <i>Cancer Investigation</i> , 2014, 32, 445-450.	0.6	0
108	Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single institution experience. <i>Radiologia Medica</i> , 2013, 118, 570-582.	4.7	3

#	ARTICLE	IF	CITATIONS
109	Treatment of invasive male breast cancer: a 40-year single-institution experience. <i>Radiologia Medica</i> , 2013, 118, 476-486.	4.7	2
110	Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 521-528.	1.2	32
111	Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 Patients treated with a prospective margin-directed policy. <i>Radiotherapy and Oncology</i> , 2013, 108, 273-278.	0.3	20
112	Role of radiotherapy boost in women with ductal carcinoma in situ: A single-center experience in a series of 389 patients. <i>European Journal of Surgical Oncology</i> , 2013, 39, 613-618.	0.5	29
113	Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen. <i>Clinical Breast Cancer</i> , 2013, 13, 247-253.	1.1	10
114	Simultaneous integrated boostâ€“intensityâ€“modulated radiotherapy in head and neck cancer. <i>Laryngoscope</i> , 2013, 123, E97-103.	1.1	16
115	Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report. <i>Tumori</i> , 2013, 99, e233-6.	0.6	2
116	Pediatric Primary Anaplastic Ganglioglioma: A Case Report and Review of the Literature. <i>Pediatric Neurosurgery</i> , 2012, 48, 35-41.	0.4	13
117	Prognostic factors and clinical features in patients with leptomeningeal metastases from breast cancer: a single center experience. <i>Journal of Chemotherapy</i> , 2012, 24, 279-284.	0.7	27
118	Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph nodeâ€“negative breast cancer. <i>Cancer</i> , 2012, 118, 3236-3243.	2.0	39
119	Adjuvant Radiotherapy for a Prostate Cancer After Renal Transplantation and Review of the Literature. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1282-1286.	0.6	13